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Combination treatment with radiation therapy or chemotherapy can sensitize TRAIL 
resistant tumor cells and vice versa. In this study, we show that treatment of TRAIL 
resistant HeLa S3 cells with 10 µM of the proteasome inhibitor MG132 combined with 
a low concentration (10 ng/ml) of a DR5 selective TRAIL variant is able to induce 
apoptosis in this cell line in a synergistic fashion. Moreover, this combination is 
significantly more potent than similar concentrations of MG132 and rhTRAIL. 
Preliminary results suggest that also the sequential combination of 10 Gγ ionizing 
radiation and low concentrations (5-10 ng/ml) of the DR5 selective TRAIL variant is 
able to induce significantly more apoptosis in HeLa S3 cells than either treatment 
alone and that this combination is more potent than 10 Gγ ionizing radiation and 5-10 
ng/ml rhTRAIL. Although the exact molecular mechanism of the enhanced potency of 
the DR5 selective TRAIL variant when used in combination with radiotherapy or a 
proteasome inhibitor remains to be elucidated, DR5 receptor selective TRAIL 
variants permit novel targeted and tumor selective anti-cancer therapies. 
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Tumor necrosis factor (TNF) related apoptosis inducing-ligand (TRAIL) is currently 
attracting great interest as a potential cancer therapeutic. TRAIL in its soluble form 
selectively induces apoptosis in tumor cells in vitro and in vivo in several preclinical 
models19. TRAIL binds to five cognate receptors; to the death receptors DR4 (TRAIL-R1) 
and DR5 (TRAIL-R2) and to the decoy receptors DcR1 (TRAIL-R3), DcR2 (TRAIL-R4) 
and osteoprotegerin (OPG)19. Binding of TRAIL to the DR4 and DR5 receptors induces 
apoptosis by activating the cell-extrinsic or death receptor-mediated apoptosis pathway. 
Upon binding with TRAIL the death receptors trimerize and an intracellular death-inducing 
signaling complex (DISC) is assembled; the intracellular death domains of DR4 and DR5 
recruit Fas associated death domain (FADD)20-22, which bind and activate the apoptosis 
initiator caspases 8 and 1023-26. This leads to the activation of the apoptosis executioner 
caspase 3, followed by the activation of other proteases and nucleases resulting finally in 
apoptosis27,28. This process can be inhibited by the cellular FLICE like-inhibitory protein 
(cFLIP), an inhibitor of caspase activation, or by inhibitor of apoptosis proteins (IAPs) such 
as X-IAP29. DcR1 or DcR2 do not contain an intracellular death domain or contain a 
truncated death domain, respectively. Binding to these receptors does not induce apoptosis, 
in contrast, it could prevent apoptosis by sequestering available TRAIL or by interfering in 
the formation of a TRAIL DR4 or DR5 signaling complex30. The physiological relevance 
of the third decoy receptor OPG is unclear; this soluble receptor is able to bind TRAIL 
although the affinity at physiological temperature is rather low188. Recently, we designed 
DR5 selective TRAIL variants, which show reduced binding to the DR4 receptor as well as 
reduced binding to both decoy receptors and OPG108. 
 
It has been shown that TRAIL treatment enhances the efficacy of irradiation and 
chemotherapeutic treatment or, alternatively, these treatments can resensitize TRAIL 
resistant tumor cells198. Moreover, in experimental anti-cancer treatment, the receptors DR4 
and/or DR5 were shown to be up-regulated after treatment with chemotherapeutic drugs or 
irradiation and the response to TRAIL-induced apoptosis was significantly 
increased19,107,182. Exposure to most anticancer chemotherapeutics and irradiation triggers 
the cell-intrinsic or mitochondrial apoptosis pathway, this in contrast to TRAIL treatment 
which induces the cell-extrinsic or death receptor-mediated apoptosis pathway28. Upon 
activation of the cell-intrinsic or mitochondrial pathway by DNA damaging 
chemotherapeutics or irradiation, apoptogenic factors such as cytochrome-c and 
smac/diablo are released from the mitochondria into the cytosol by pro-apoptotic members 
of the Bcl-2 family. Cytochrome-c binds in the cytosol the adaptor protein apoptosis–
activating factor-1 (Apaf-1), forming an “apoptosome” resulting in the recruitment and 
activation of apoptosis initiator caspase—caspase 9—of the cell-intrinsic pathway. Similar 
to the activation of the initiator caspase of the death receptor-mediated apoptosis pathway, 
activation of caspase 9 also results in the activation of the downstream “executioner” or 
effector caspases (caspase 3, 6 and 7), ultimately resulting in apoptosis105,199. 
 
The death receptor-mediated pathway and the mitochondrial pathway are connected via the 
pro-apoptotic Bcl-2 family member Bid, a substrate of caspase 3 and 8. Depending on the 
particular cell type, activation of the effector caspases (e.g. caspase 3) is induced directly 
after stimulating the death-receptor pathway and subsequent activation of caspase 8 (type I 
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cells). However in type II cells, amplification via the mitochondrial pathway through 
activated truncated Bid (tBid) is required to activate the effector caspases. Translocation of 
tBid to the mitochondria triggers the release of cytochrome-c and smac/diablo, in 
cooperation with two other pro-apoptotic Bcl-2 family members Bak or Bax. A decrease in 
expression levels of these pro-apoptotic Bcl-2 family members or increases in the 
expression levels of anti-apoptotic Bcl-2 family members such as Bcl-2 or Bcl-xL, disrupts 
apoptotic signaling of the cell-intrinsic pathway and causing resistance to anticancer 
therapy19,29,198. 
 
Whereas apoptosis induction by the intrinsic pathway often depends on the presence of 
functional p53, TRAIL has been shown to induce apoptosis independently of p53 function. 
Irradiation appears to specifically up-regulate DR5 receptor expression and the combination 
of irradiation and TRAIL treatment has been demonstrated to have an additive or 
synergistic effect107,200. Up-regulation of DR5 receptor expression in response to irradiation 
was demonstrated being both dependent as well as independent on the presence of 
functional p53200-202. Treatment with proteasome inhibitors have also been reported to up-
regulate DR5 and/or DR4 receptor expression203-205. Proteasome inhibitors can sensitize 
tumor cells to TRAIL-mediated apoptosis by several mechanisms including, inactivation of 
the nuclear factor kappa Beta (NF-κΒ) pathway, modulating the balance between pro- and 
anti-apoptotic Bcl-2 members resulting in the accumulation of pro-apoptotic members, 
reducing levels of IAPs (e.g. X-IAP), reduction of cFLIP levels, or reduced degradation of 
p53. In the present study, we have investigated the co-treatment of TRAIL or a DR5 
selective variant in combination with a proteasome inhibitor or irradiation in the human 
cervical cancer cell line HeLa S3. We reasoned that a DR5 receptor selective TRAIL 
variant in combination with irradiation or a proteasome inhibitor might show enhanced 
synergistic or additive activity when compared to rhTRAIL WT in apoptosis induction. The 
HeLa S3 cell line has a wild type functional p53206 and harbors the HPV18 oncogene207. 
This oncogene encodes the HPV E6 protein which inactivates p53 by targeting it to the 
proteasome for degradation208. In addition, this cell line is only slightly sensitive to TRAIL 
induced apoptosis but can be sensitized when treated with a proteasome inhibitor205. 
Preliminary results indicate an enhanced synergistic behavior between the DR5 selective 
TRAIL variant in combination with a proteasome inhibitor or irradiation when compared to 
rhTRAIL WT. Combination of a DR5 selective TRAIL variant with a proteasome inhibitor 




Treatment with radiation therapy and rhTRAIL WT or D269H/E195R. 
The viability of HeLa cells upon treatment with rhTRAIL WT or DR5 selective TRAIL 
variant D269H/E195R in combination with 10 Gγ ionizing radiation was determined using 
a MTT assay. After exposing the cells to the required dose of ionizing radiation (0.9 
Gy/min, 10 Gy total) the cells were further incubated with 5, 10 or 50 ng/ml rhTRAIL WT 
or D269H/E195R. Cells treated only with 5 or 50 ng/ml rhTRAIL WT or D269H/E195R 
were used as control. After treatment the viability of the cells was assessed using a MTT 
assay. Upon treatment with only rhTRAIL WT or D269H/E195R the viability of the HeLa 
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cells was hardly affected, at the highest concentration tested (50 ng/ml) rhTRAIL WT 
reduces the viability with less than 20% and D269H/E195R causes a reduction in viability 
of less than 5%. This low sensitivity of HeLa cells for rhTRAIL WT is in agreement with a 
previous study of Hougardy et al.,205. Conversely, after an accumulated dose of 10 Gy of 
ionizing irradiation the response to rhTRAIL WT treatment was markedly increased. The 
decrease in viability of the HeLa cells sequentially treated with 10 Gy of irradiation and 50 
ng/ml rhTRAIL WT was more than doubled when compared to cells only treated with 50 
ng/ml rhTRAIL WT (Figure 1a). The combination of D269H/E195R and radiotherapy gave 
even a more pronounced effect. Although the maximum effect on viability of 
D269H/E195R in combination with radiation therapy was equal to the effect of rhTRAIL 
WT at 50 ng/ml in combination with radiation therapy, this effect was already reached at 5 
ng/ml while rhTRAIL WT reached the same level of effect only at 50 ng/ml (Figure 1a). In 
a second experiment the more potent effect of D269H/E195R in combination with 
radiotherapy was confirmed, at concentrations of both 1 ng/ml and 5 ng/ml the decrease in 
viability was more pronounced than that of similar concentrations of rhTRAIL WT (Figure 
1b).  
 
Figure 1. A and B. Cell death induced by radiation therapy in combination with rhTRAIL WT or a DR5 selective 
TRAIL variant in HeLa cells. Cells were sequentially treated with 10 Gy of irradiation and 1-50 ng/ml rhTRAIL 
WT or D269H/E195R. Figure 1A and 1B are two independent experiments; the error bars depict the variation 
(standard deviation) within a single experiment. Legend; WT: rhTRAIL WT; D/E: D269H/E195R; T: treated with 
1-50 ng/ml rhTRAIL WT or D269H/E195R; R: 10 Gy of irradiation. 
In order to confirm that the observed increase in cell death upon treatment with rhTRAIL 
WT or D269H/E195R in combination with radiotherapy was indeed caused by apoptosis, 
HeLa cells were treated with 10 ng/ml rhTRAIL WT or D269H/E195R with and without 10 
Gy ionizing radiation and apoptosis was determined with acridine orange staining. The 
combination of 10 ng/ml rhTRAIL WT or D269H/E195R with 10 Gy ionizing radiation 
induces a high level of apoptosis (>50%) while when treating cells with only 10 ng/ml 
rhTRAIL WT or D269H/E195R only 5% of the cells appear to be apoptotic (Figure 2). 
Taken together, these results suggest that the DR5 selective TRAIL variant might be more 
potent than rhTRAIL WT when combined with radiotherapy. Both the DR5 selective 
variant and rhTRAIL WT when combined with radiotherapy appear to exert their effect by 
an increase in the level of apoptosis.  
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Figure 2. Apoptosis induced in HeLa cells by radiation therapy in combination with rhTRAIL WT or a DR5 
selective TRAIL variant. Cells were sequentially treated with 10 Gy of irradiation and 10 ng/ml rhTRAIL WT or 
D269H/E195R. Legend; WT: rhTRAIL WT; D/E: D269H/E195R; -RT: no radiation therapy; +RT: 10 Gy of 
irradiation. 
Treatment with proteasome inhibitor and rhTRAIL WT or D269H/E195R 
Recently, it was demonstrated that co-treatment of HeLa cells with the proteasome inhibitor 
MG132 could sensitize these cells for TRAIL induced apoptosis205. Both the DR5 receptor 
and, to a lesser extend, the DR4 receptor were found to be upregulated in response to 
treatment with MG132. However, the apoptotic inducing capability of rhTRAIL WT upon 
co-treatment with MG132 could partially be inhibited by an antagonistic DR4 antibody205. 
To examine the efficacy of a DR5 selective TRAIL variant in this setting, HeLa cells were 
pretreated with 10 µM of the proteasome inhibitor MG132. After 2 hr, 10 ng/ml rhTRAIL 
WT or D269H/E195R were added to the cells and incubated for another 4 and 6 hours. 
Untreated HeLa cells and HeLa cells treated only with 10 ng/ml rhTRAIL WT, 
D269H/E195R or 10 µM MG132 were used as controls. Following incubation the number 
of apoptotic cells was determined using acridine orange staining. After incubation for 4 and 
6 hours, cells treated with only rhTRAIL WT, D269H/E195R or MG132 showed only a 
small increase in the number of apoptotic cells when compared to the untreated cells, in all 
cases the percentage of apoptotic cells was well below 10% (Figure 3). Treatment with 
MG132 and rhTRAIL WT for 6 h, caused a ~2-fold increase in the number of apoptotic 
HeLa cells when compared to the controls. In cells treated with MG132 and D269H/E195R 
this effect was much more pronounced. Even after 4 h of incubation with D269H/E195R 
the number of apoptotic cells was more than 3-fold higher then after treatment with only 
MG132 or D269H/E195R. A 7-fold increase in the number of apoptotic cells was observed 
after 6 h of incubation with D269H/E195R and MG132 (Figure 3). Both at 4 h as well as at 
6 h of treatment with D269H/E195R in combination with MG132, this combination was 
significantly more potent than the combination of rhTRAIL WT and MG132 (p = 0.006 and 
p = 0.02, for 4 and 6 h treatment, respectively). These results demonstrate that TRAIL 
variants can be used to trigger apoptosis through a DR5 receptor mediated pathway when 
combined with a proteasome inhibitor in HeLa cells in a synergistic fashion. Moreover, the 
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DR5 selective TRAIL variant shows higher potency than rhTRAIL WT when used in 
combination with a proteasome inhibitor. 
 
Figure 3. Combined treatment of proteasome inhibitor and rhTRAIL WT or DR5 selective TRAIL variant in 
HeLa cells. Legend; WT: 10 ng/ml rhTRAIL WT; D/E: 10 ng/ml D269H/E195R; PI: proteasome inhibitor MG132 
(10 µM). Apoptosis was determined after 4 and 6 hr of treatment with rhTRAIL WT or D269H/E195R. Mean and 




TRAIL interacts with five different receptors of the TNF-R family; however, only DR4 and 
DR5 transmit the apoptosis inducing signal. Furthermore, it was shown that the expression 
levels of DR5 were up-regulated in cancer cells in response to certain chemotherapeutic 
drugs (15) and in response to ionizing radiation (16). Therefore, we recently developed 
DR5 receptor selective variants of TRAIL in order to permit novel tumor selective anti-
cancer therapies108. 
 
Treatment of HeLa cancer cells with either rhTRAIL WT, D269H/E195R or the 
proteasome inhibitor MG132 only gave a marginal effect. However, treatment of HeLa 
cells with MG132 followed by treatment with rhTRAIL WT or D269H/E195R was shown 
to have a synergistic effect, this treatment resulted in a manifest increase in cell death when 
compared to either treatment alone. Radiotherapy as well sensitized HeLa cells towards 
apoptosis induced by rhTRAIL WT or D269H/E195R. In this study we compared the 
efficacy of rhTRAIL WT and the DR5 selective TRAIL variant D269H/E195R, the 
combination of the proteasome inhibitor MG132 and D269H/E195R was shown to be 
significantly more potent in the induction of apoptosis than the combination MG132 and 
rhTRAIL WT. Furthermore, the available data indicates that the combination of 
radiotherapy and D269H/E195R might be more potent than the combination of 
radiotherapy and rhTRAIL WT. 
Sensitization of TRAIL resistant cancer cells by chemotherapeutics or radiotherapy are 
mediated by both p53 dependent and p53 independent mechanisms202. Activation of p53 by 
DNA damaging stressors or inhibition of p53 degradation by using proteasome inhibitors, 
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causes an increase in the expression levels of several proteins implicated in apoptosis 
signaling198,209. DNA damage induced p53 activation results in transcriptional activation of 
FAS and DR5 death receptors through their p53 transactivation sites in the genes encoding 
these death receptors. Other examples are the activation in a p53 dependent manner of Bax, 
Bid, Noxa and other pro-apoptotic Bcl-2 members and the p53 dependent transcriptional 
activation of caspase 1029,198,209. Chemotherapeutic drugs induce the expression levels of 
DR4 and DR5 and enhance the efficacy of TRAIL induced apoptosis, both in p53 wild-type 
and p53 negative or mutant cells198,210,211. DR5 up-regulation in response to treatment with 
the proteasome inhibitor MG132 was found to be induced both at the transcriptional level 
and protein level through the CCAAT/Enhancer-binding protein homologues protein 
(CHOP) and this up-regulation was (probably) independent from p53 function212. Up-
regulation of DR5 receptor expression in response to irradiation was demonstrated being 
both dependent as well as independent on the presence of functional p53107,200-202,213. 
However, the surface expression level of DR4 or DR5 receptors does not always correlate 
with the sensitivity for TRAIL induced apoptosis mediated by those receptors108,214. 
Similarly, no tight correlation was observed between irradiation induced DR5 up-regulation 
and tumor cell sensitization to TRAIL200. Apart from DR4 and DR5 receptor expression 
levels and the involvement of p53, the direct contribution of pro-apoptotic Bcl-2 members 
in the sensitization to TRAIL induced apoptosis in response to irraditiation or treatment 
with proteasome inhibitors is equally complex. In irradiation-induced sensitization to 
TRAIL induced apoptosis the levels of Bax and Bak were upregulated in a prostate cancer 
model202, in another prostate cancer model and in a colon cancer model Bax was reported to 
be essential and Bak to be dispensable for the synergy between TRAIL induced apoptosis 
and irradiation215, and in a mesothelioma cancer model Bid was found to be essential216. 
The sensitization to TRAIL induced apoptosis in response to treatment with the proteasome 
inhibitor MG132 was reported to be independent of Bax in a colon cancer model204. The 
pro-apoptotic Bcl-2 family member Bik was reported to be involved in the sensitization 
toward TRAIL induced apoptosis upon treatment with proteasome inhibitors in colon 
cancer models217. 
In a recent study, Hougardy et al., examined the effects of combination treatment of a 
proteasome inhibitor with rhTRAIL WT in HeLa cells205. Treatment with the proteasome 
inhibitor MG132 strongly sensitized cells to TRAIL induced apoptosis. In response to 
treatment with MG132 both the DR5 receptor and, to a lesser extend, the DR4 receptor 
were up-regulated. DR5 receptor up-regulation was found to be partially dependent on p53 
up-regulation while DR4 up-regulation was independent of p53, as was the effect on 
TRAIL induced apoptosis. In addition, inactivation of XIAP was found to contribute to 
proteasome inhibitor-induced sensitization to TRAIL-induced apoptosis205. Radiotherapy 
also induced DR5 membrane expression levels in HeLa cells without affecting DR4 
receptor expression levels (Maduro et al., manuscript in preparation). The increase in DR5 
receptor membrane expression levels was found to be dependent on an increase in p53 
expression levels and the increase in apoptosis after irradiation was not dependent on 
increased p53 expression levels. Irradiation did not change the expression levels of the pro- 
and anti- apoptotic mitochondrial proteins like Bax, Bak or Bcl2. Surprisingly, using 
siRNA to block DR4 and DR5 receptor expression, it was found that both the DR4 and 
DR5 receptors mediate the TRAIL induced apoptosis after irradiation rather than the DR5 
receptor (Maduro et al., manuscript in preparation). In the present study we demonstrate 
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that triggering of the DR5 receptor mediated pathway by a DR5 selective TRAIL variant 
also efficiently induces apoptosis after sensitization by a proteasome inhibitor or ionizing 
radiation. How to explain the results in the present study with the observed DR4 
dependency in the previous study? Blocking experiments with siRNA and antagonistic 
antibodies in the previous study revealed that at least a fraction of the cell death could still 
be mediated by the DR5 receptor. A partial explanation of the observed efficacy of the DR5 
selective TRAIL variant could then be the higher affinity of D269H/E195R for the DR5 
receptor and the lower affinity for decoy receptors108, allowing D269H/E195R to make 
more efficiently use of the available (functional) DR5 receptors than similar concentrations 
of rhTRAIL WT. Additionally, the observed efficacy of the DR5 selective TRAIL variant 
could also be in part due to utilizing DR5 receptor-induced Caspase 10 mediated apoptosis. 
It was previously demonstrated that at low TRAIL concentrations or at early assessed time 
points TRAIL could induce caspase 10 mediated apoptosis via a DR5-mediated mechanism 
but not via a DR4-mediated mechanism218. The DR5 selective variant could possibly trigger 
this particular route with enhanced efficacy compared to rhTRAIL WT due to its higher 
affinity for DR5 and its inability to form DR4/DR5 heteromeric complexes as, in contrast, 
has been demonstrated for rhTRAIL WT23. Further research using receptor specific 
antagonistic antibodies and siRNA experiments should further elucidate the role of each 
death and decoy receptor and of intracellular components responsible for the observed 
potency of the DR5 selective TRAIL variant. Despite the uncertainty of the exact molecular 
mechanism responsible for the observed potency of the DR5 selective TRAIL variant in 
HeLa cells, the DR5 receptor is a viable target for receptor mediated apoptosis by DR5 
selective ligands in combination with radiotherapy or a proteasome inhibitor. Several 
examples support this notion; Buchsbaum and co-workers successfully used the agonistic 
anti-DR5 mAb TRA-8 in combination with radiotherapy and/or chemotherapy in vitro and 
in vivo in breast cancer models and in cervical cancer models219,220. Treatment with a 
proteasome inhibitor or radiotherapy was able to enhance, in additive or synergistic 
manner, the apoptosis inducing activity of the agonistic anti-DR5 mAb HGS-ETR2 in 
various cell lines214,221,222. In an in vivo Colo205 xenograft model this latter antibody was 
found to have a higher activity than the agonistic anti-DR4 mAb HGS-ETR1222.  
 
Unlike other apoptosis inducing TNF family members, soluble TRAIL appears to be 
inactive against normal healthy tissue13. Reports in which TRAIL induces apoptosis in 
normal cells could be attributed to the specific preparations of TRAIL used14,15. The few 
available tests regarding DR5 selective TRAIL variants108,109 and the extensive available 
information regarding several TRAIL death receptor specific antibodies (see for example 
Ichikawa et al.,180) indicate that death receptor specific ligands, just as normal promiscuous 
rhTRAIL WT, also have low toxicity in normal cells. In this respect, rhTRAIL WT is 
currently evaluated in a phase I clinical trial and a death receptor specific ligand (the 
agonistic anti-DR4 mAb HGS-ETR1) is currently already being evaluated in a phase II 
clinical trail in combination with the proteasome inhibitor bortezomib (PS-341). However, 
combination treatment with chemotherapeutics or radiotherapy might also sensitize normal 
healthy tissues to TRAIL induced apoptosis. This must be properly investigated for both 
rhTRAIL WT as well as any death receptor specific ligands, especially in cases when both 
treatments have to be systemically administered or applied. Encouragingly, sensitization to 
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TRAIL induced apoptosis in combination with 10 Gy irradiation could not be demonstrated 
using a panel of several normal non-cancer cell lines including hepatocytes200.  
 
In conclusion, our results show that a combination of the DR5 selective TRAIL variant 
D269H/E195R and the proteasome inhibitor MG132 is significantly more potent in the 
induction of apoptosis than the combination MG132 and rhTRAIL WT. Preliminary results 
also suggest that the combination of radiotherapy and D269H/E195R is more potent than 
the combination of radiation therapy and rhTRAIL WT. Although the exact molecular 
mechanism of the enhanced potency of the DR5 selective TRAIL variant when used in 
combination with radiation therapy or with a proteasome inhibitor remains to be elucidated 
and safety of these combination treatment regimens towards non cancer cells needs to be 
addressed, this DR5 receptor selective TRAIL variant permits novel targeted and tumor 








Reagents and chemicals 
Dulbecco's MEM and Nutrient Mixture F-12 (HAM) were obtained from Invitrogen-Life 
Technologies (Merelbeke, Belgium) and fetal calf serum (FCS) from Bodinco (Alkmaar, 
the Netherlands). 3-(4, 5-dimethylthiazol-2-yl) 2, 5-diphenyltetrazolium bromide (MTT) 
was purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands), dimethyl sulfoxide 
(DMSO) from Merck (Amsterdam, the Netherlands), trypsin stock (10×) solution and 
EDTA from Invitrogen-Life Technologies and the proteasome inhibitor MG132 from 
Calbiochem (Breda, the Netherlands). RhTRAIL WT and the DR5 selective TRAIL variant 
D269H/E195R108 were produced following a protocol described previously65.  
 
Cell line and cell culture 
The human cervical carcinoma cell line HeLa S3 (HeLa) was obtained from the American 
Type Culture Collection (ATCC, Manassas, VA, USA). This HeLa cell line is human 
papillomavirus type 18 (HPV-18) positive207 and contains wild-type p53206. Cells were 
grown at 37oC in a humidified atmosphere with 5% CO2 in 1:1 DMEM/HAM medium 
supplemented with 10% FCS. Cells were detached with 0.05% trypsin/0.5 mM EDTA in 
phosphate-buffered saline (PBS, 0.14 M NaCl, 2.7 M KCl, 6.4 M Na2HPO4. 2H2O, 1.5 M 
KH2PO4, pH 7.4). 
 
Irradiation 
Cells were irradiated with a 137 Cesium -ray machine (IBL 637, CIS Bio International 
Gif/Yvette, France) at 0.9 Gy/ min. After receiving the required dose of ionizing radiation 
(10 Gy) the cells were treated with 5, 10 or 50 ng/ml rhTRAIL WT or D269H/E195R. Cells 
treated only with 5 or 50 ng/ml rhTRAIL WT or D269H/E195R were used as control. To 
correct for loss of viability due to irradiation and to compare the efficacy of the TRAIL and 
D269H/E195R treatment, data was normalized to 100% viability at 0 ng/ml rhTRAIL WT 
or D269H/E195R and for each treatment all other values were calculated relative to the 
value at 0 ng/ml. 
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Cytotoxicity assay 
The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was used 
to determine the cytotoxic activity of rhTRAIL WT in combination with irradiation. In a 
96-well culture plate, 3,000 cells per well (to obtain logarithmic cell growth at day 4) were 
incubated in a total volume of 200 l. Treatment consisted of irradiation followed by 
continuous incubation with rhTRAIL WT in various concentrations. Cytotoxicity was 
determined after 4 days by adding 20 l MTT-solution and incubated for 3.5 h at 37°C. 
After centrifugation, the culture supernatant was discarded and the blue formazan crystals, 
which are only formed in living cells by oxidation, were dissolved by adding DMSO. The 
plate was read immediately at 520 nm using a microtiter plate spectrometer (Benchmark 
Microplate Reader, Bio-Rad Laboratories Inc., Veenendaal, the Netherlands). Controls 
consisted of media without cells. Cell survival was defined as the growth of treated cells 
compared to untreated cells. The assay was performed in quadruplicate. 
Proteasome inhibition 
In a 96-wells culture plate 15,000 cells per well were seeded in 100 l culture medium. 
Cells were pretreated for 2 hr with 10 µM MG132 (dissolved in DMSO) followed by 
treatment with 10 ng/ml rhTRAIL WT or D269H/E195R for 4 hr and 6 hr. At the end of the 
experimental period acridine orange was added and apoptotic cells were counted using a 
fluorescence microscope. Apoptosis was defined by the appearance of apoptotic bodies 
and/or chromatin condensation. Results are expressed as the percentage of apoptotic cells in 
a culture (by counting at least 300 cells per well). This assay was performed three times. 
 
Statistical analysis 
Statistical analysis was performed using the two sample t-test. Differences associated with 
p-values < 0.05 were considered significant. 
 
 
  
